Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#41 / 200 Total
NKGN - NKGen Biotech Inc - Stock Price Chart
TickerNKGN [NASD]
CompanyNKGen Biotech Inc
CountryUSA
IndustryBiotechnology
Market Cap41.51MEPS (ttm)-4.10
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-989.64%
Dividend-Sales Q/Q-
Insider Own60.46%Inst Own14.10%
Insider Trans0.01%Inst Trans14.16%
Short Float6.89%Earnings-
Analyst Recom-Target Price-
Avg Volume3.46M52W Range0.78 - 12.88
Apr-18-24 04:05PM NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) -16.50%
Apr-16-24 11:53PM NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023 (InvestorPlace)
Apr-11-24 08:05AM NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs (GlobeNewswire)
Mar-25-24 04:05PM NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire) -6.90%
Mar-06-24 07:52AM Why Is NKGen Biotech (NKGN) Stock Up 62% Today? (InvestorPlace) +112.30%
Mar-04-24 08:00AM NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire)
Feb-07-24 08:57AM Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies (News Direct)
Dec-29-23 07:30AM NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial (News Direct) -10.42%
Dec-28-23 04:05PM NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease (GlobeNewswire) -7.53%
Dec-27-23 08:00AM NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease (GlobeNewswire) +17.73%
XWEL - XWELL Inc - Stock Price Chart
TickerXWEL [NASD]
CompanyXWELL Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap7.31MEPS (ttm)-6.65
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y66.28%
P/S0.24EPS next 5Y20.00%
P/B0.56EPS Q/Q51.28%
Dividend-Sales Q/Q-2.05%
Insider Own2.96%Inst Own8.64%
Insider Trans0.00%Inst Trans-
Short Float1.68%EarningsApr 16/a
Analyst Recom1.00Target Price7.00
Avg Volume12.11K52W Range1.26 - 6.40
Apr-19-24 09:00AM XWELL Inc (XWEL) Q4 2023 Earnings Call Transcript Highlights: Strategic Expansions and Cost ... (GuruFocus.com)
Apr-17-24 08:48AM XWELL, Inc. (NASDAQ:XWEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-16-24 11:52PM XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:30PM XWELL, Inc. Reports Fiscal Year 2023 Results (GlobeNewswire)
08:00AM XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024 (GlobeNewswire)
Apr-01-24 04:30PM XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K (GlobeNewswire)
Mar-12-24 07:01AM CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago (PR Newswire)
Feb-14-24 08:00AM XWELL Advances Expansion Plan Outside the Airport with Three New Naples Wax and Skin Care Locations (GlobeNewswire) +11.18%
Jan-04-24 08:00AM XWELL Announces Plans to Open an XpresSpa in THE PENN DISTRICT (GlobeNewswire)
Dec-15-23 04:15PM XWELL Appoints Veteran Consumer & Wellness Entrepreneur Ga lle Wizenberg to its Board of Directors (GlobeNewswire)
FAAS - DigiAsia Corp. - Stock Price Chart
TickerFAAS [NASD]
CompanyDigiAsia Corp.
CountrySingapore
IndustrySoftware - Infrastructure
Market Cap90.65MEPS (ttm)0.11
P/E78.08EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B4.65EPS Q/Q-112.90%
Dividend-Sales Q/Q-
Insider Own42.49%Inst Own13.97%
Insider Trans0.01%Inst Trans1.69%
Short Float0.05%Earnings-
Analyst Recom-Target Price-
Avg Volume76.66K52W Range4.76 - 13.99
Jan-05-23 05:00PM StoneBridge Acquisition Corporation (NASDAQ: APAC) Announces Business Combination Agreement with Southeast Asias Fintech-As-A-Service (FaaS) player DigiAsia (GlobeNewswire)
Jul-01-22 08:42AM What Type Of Shareholders Own The Most Number of StoneBridge Acquisition Corporation (NASDAQ:APAC) Shares? (Simply Wall St.)
Jun-01-22 04:20PM Freehold Royalties Ltd. Announces New Board Members (GlobeNewswire)
YYGH - YY Group Holding Limited Class A Ordinary Shares - Stock Price Chart
TickerYYGH [NASD]
CompanyYY Group Holding Limited Class A Ordinary Shares
CountrySingapore
IndustryPersonal Services
Market Cap-EPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q42.30%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume805.10K52W Range2.04 - 4.70
Today 11:39AM YY Group Announces Closing of Initial Public Offering (GlobeNewswire)
Apr-19-24 04:56PM YY Group Announces Pricing of Initial Public Offering (GlobeNewswire)
MNDR - Mobile health Network Solutions - Stock Price Chart
TickerMNDR [NASD]
CompanyMobile health Network Solutions
CountrySingapore
IndustryHealth Information Services
Market Cap855.10MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own53.46%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float-Earnings-
Analyst Recom1.00Target Price7.00
Avg Volume6.65M52W Range4.79 - 29.50
Apr-23-24 09:00AM Mobile-health Network and Online Pharmacy, Lifepack, Sign Partnership Facilitating Cooperation in Singapore and Indonesia (GlobeNewswire)
Apr-22-24 09:00AM APAC Telehealth Leader MNDR Expects Revenue Growth in H12024 vs H12023 (GlobeNewswire) -12.54%
Apr-17-24 08:55AM Mobile-health Network Solutions Ranked Number 41 in Financial Times Listing of 500 High-growth Asia-Pacific Companies (GlobeNewswire)
Apr-15-24 08:30AM Mobile-health Network Solutions Makes History as First APAC Telehealth Company Listed on US Stock Exchange (GlobeNewswire) +11.00%
Apr-12-24 07:28PM Mobile-health Network Solutions Announces Closing of Initial Public Offering (GlobeNewswire) +47.06%
Apr-09-24 06:30PM Mobile-health Network Solutions Announces Pricing of $9 Million Initial Public Offering (GlobeNewswire)
VTNR - Vertex Energy Inc - Stock Price Chart
TickerVTNR [NASD, RUT]
CompanyVertex Energy Inc
CountryUSA
IndustryOil & Gas Refining & Marketing
Market Cap134.19MEPS (ttm)-1.50
P/E-EPS this Y63.46%
Forward P/E-EPS next Y-22.36%
PEG-EPS past 5Y-45.16%
P/S0.04EPS next 5Y20.00%
P/B0.68EPS Q/Q-219.01%
Dividend-Sales Q/Q-16.38%
Insider Own9.34%Inst Own45.74%
Insider Trans-1.16%Inst Trans7.51%
Short Float20.62%EarningsMay 09/b
Analyst Recom2.43Target Price2.92
Avg Volume2.62M52W Range0.95 - 8.17
Apr-18-24 07:00AM Vertex Energy Provides Operational Update for First Quarter 2024 (Business Wire) +33.78%
Apr-10-24 04:30PM Vertex Energy Schedules First Quarter 2024 Earnings Release and Conference Call (Business Wire) -5.93%
Feb-29-24 11:41AM Vertex Energy, Inc. (NASDAQ:VTNR) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.88%
Feb-28-24 11:47PM Q4 2023 Vertex Energy Inc Earnings Call (Thomson Reuters StreetEvents) -24.11%
09:36PM CORRECTING and REPLACING Vertex Energy Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
06:36AM Vertex Energy Inc (VTNR) Faces Net Loss in Q4 and Full Year 2023 Amid Renewables Segment Challenges (GuruFocus.com)
06:00AM Vertex Energy Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Jan-31-24 09:09AM Vertex Energy Announces Fourth Quarter 2023 Earnings Release and Conference Call Date (Business Wire)
Jan-27-24 05:29AM 18 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Jan-26-24 09:14AM Vertex (VTNR) Expects Reduced Throughput Volumes in Q4 2023 (Zacks) +6.18%
DATS - DatChat Inc - Stock Price Chart
TickerDATS [NASD]
CompanyDatChat Inc
CountryUSA
IndustrySoftware - Application
Market Cap3.76MEPS (ttm)-4.06
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-2.18%
P/S-EPS next 5Y-
P/B0.42EPS Q/Q61.25%
Dividend-Sales Q/Q-95.64%
Insider Own8.94%Inst Own0.64%
Insider Trans0.00%Inst Trans-
Short Float2.08%Earnings-
Analyst Recom-Target Price-
Avg Volume129.67K52W Range1.08 - 8.49
Apr-02-24 09:53AM DATS Stock Earnings: DatChat Reported Results for Q4 2023 (InvestorPlace)
Feb-29-24 08:47AM DatChat Unleashes AI Dog Racing and Full Monetization in Habytat Metaverse Expansion (GlobeNewswire) -5.81%
Jan-19-24 04:05PM DatChat, Inc. Announces Closing of $1.8 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -9.62%
Jan-17-24 08:36AM Why Is DatChat (DATS) Stock Down 37% Today? (InvestorPlace) -49.37%
08:00AM DatChat, Inc. Announces Pricing of $1.8 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Jan-16-24 04:05PM DatChat, Inc. Announces Proposed Underwritten Public Offering of Common Stock (GlobeNewswire) +51.79%
02:38PM Why Is DatChat (DATS) Stock Up 65% Today? (InvestorPlace)
10:30AM DatChat Issues Shareholder Letter and Provides Corporate Update (GlobeNewswire)
09:00AM DatChat Announces Planned Spin-off of its Habytat Platform Business into a New Standalone Public Company (GlobeNewswire)
Dec-28-23 08:47AM DatChat Unveils the Habytat AI Social Gaming & Developer Platform (GlobeNewswire) +58.25%
CYCC - Cyclacel Pharmaceuticals Inc - Stock Price Chart
TickerCYCC [NASD]
CompanyCyclacel Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap2.77MEPS (ttm)-27.02
P/E-EPS this Y49.98%
Forward P/E-EPS next Y-
PEG-EPS past 5Y32.13%
P/S6.60EPS next 5Y-
P/B3.66EPS Q/Q30.27%
Dividend-Sales Q/Q-
Insider Own8.89%Inst Own7.12%
Insider Trans7.27%Inst Trans-
Short Float2.03%EarningsMar 19/a
Analyst Recom1.00Target Price11.00
Avg Volume45.08K52W Range1.52 - 13.20
Apr-01-24 09:15AM Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer (GlobeNewswire)
Mar-20-24 10:05AM Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace) -6.37%
04:05PM Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 04:05PM Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 09:15AM Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) +5.06%
Mar-06-24 09:15AM Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit (GlobeNewswire) -8.49%
Feb-20-24 09:15AM Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference (GlobeNewswire)
Jan-30-24 09:15AM Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer (GlobeNewswire)
Jan-09-24 09:07AM Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today? (InvestorPlace)
IKT - Inhibikase Therapeutics Inc - Stock Price Chart
TickerIKT [NASD]
CompanyInhibikase Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap11.73MEPS (ttm)-3.62
P/E-EPS this Y51.12%
Forward P/E-EPS next Y22.92%
PEG-EPS past 5Y-23.31%
P/S45.11EPS next 5Y-
P/B1.02EPS Q/Q33.63%
Dividend-Sales Q/Q-100.00%
Insider Own14.50%Inst Own7.16%
Insider Trans0.00%Inst Trans-20.47%
Short Float0.37%EarningsMar 27/a
Analyst Recom1.00Target Price17.50
Avg Volume138.89K52W Range0.79 - 4.35
Apr-18-24 04:30PM Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Apr-03-24 08:05AM Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-02-24 10:25AM Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 09:06PM Q4 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.09%
Mar-27-24 10:53PM IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:15PM Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-07-24 08:30AM Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (GlobeNewswire)
Feb-28-24 04:05PM Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Feb-15-24 09:55AM Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now (Zacks) -6.69%
Feb-07-24 07:55AM Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers (GlobeNewswire) -8.72%
BTCY - Biotricity Inc - Stock Price Chart
TickerBTCY [NASD]
CompanyBiotricity Inc
CountryUSA
IndustryMedical Devices
Market Cap12.43MEPS (ttm)-1.28
P/E-EPS this Y31.42%
Forward P/E-EPS next Y72.26%
PEG-EPS past 5Y-5.62%
P/S1.07EPS next 5Y-
P/B-EPS Q/Q-272.34%
Dividend-Sales Q/Q20.89%
Insider Own16.29%Inst Own4.74%
Insider Trans0.00%Inst Trans-19.67%
Short Float4.54%EarningsFeb 20/a
Analyst Recom3.00Target Price4.00
Avg Volume97.28K52W Range0.70 - 4.45
Apr-18-24 07:00AM Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics (ACCESSWIRE) +16.54%
Apr-16-24 07:00AM Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network (ACCESSWIRE) -10.45%
Apr-04-24 09:55AM Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-02-24 07:15AM Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities (ACCESSWIRE) -7.69%
Mar-28-24 10:00AM LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +8.82%
08:15AM Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals (ACCESSWIRE)
Mar-21-24 09:20AM Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert (ACCESSWIRE) -9.55%
Mar-14-24 08:50AM Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY) (Zacks)
Mar-12-24 08:45AM Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud (ACCESSWIRE)
Mar-07-24 12:00PM Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know (Zacks) +37.75%
12345678910⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.